

Angiotensin Converting Enzyme Inhibitors

Scientific Basis for Clinical Use
SECOND EDITION

Lionel H. Opie



Generic and Trade Names of ACE Inhibitors	xi
Introduction by V. Dzau	xiii
Foreword to the First Edition by A. Zanchetti	xv
Preface	xvii
Preface to the First Edition	xviii
 CHAPTER 1 The Renin-Angiotensin-Aldosterone System and Other Proposed Sites of Action of Angiotensin Converting Enzyme Inhibitors	 1
The renin-angiotensin-aldosterone system	1
Angiotensin-II as growth factor in vessels and heart	7
Renal and adrenal interactions	9
Sodium status, renin, and ACE inhibitor efficacy	11
Autonomic interactions	13
Kallikrein-kinin system and bradykinin	14
Tissue renin-angiotensin systems	16
Summary	18
References	19
 CHAPTER 2 ACE Inhibitors for Hypertension	 23
Mechanisms for antihypertensive effects of ACE inhibitors	23
ACE inhibitors as monotherapy in hypertension	27
Comparative studies with ACE inhibitors in mild to moderate hypertension	29
Large multidrug studies	49
ACE inhibitor therapy for severe or refractory hypertension	52
ACE inhibitors in special groups of patients	54
Acute testing of ACE inhibitors	57
Comparative evaluation of ACE inhibitors as antihypertensive agents	58
Summary	62
References	63
 CHAPTER 3 ACE Inhibitors and the Kidney	 71
Angiotensin-II and renal physiology	71
Intraglomerular hypertension and ACE inhibition	74
Glomerular injury in hypertension	75
Nondiabetic progressive renal failure	77
ACE inhibitors and exaggeration of circulatory-induced renal failure	78
ACE inhibitors, renal artery stenosis, and renovascular hypertension	79

vi	Contents
ACE inhibitors and diagnosis of renin-dependent hypertension	83
Renal side-effects of ACE inhibitors	84
Summary	84
References	85
CHAPTER 4 ACE Inhibitors and the Heart	88
The myocardium	88
ACE inhibitors and left ventricular hypertrophy	94
Renin-sodium profile, angiotensin, and risk of myocardial infarction	98
ACE inhibitors and coronary artery disease	99
ACE inhibitors and early phase acute myocardial infarction	102
ACE inhibitors and reperfusion injury	104
ACE inhibitors and postinfarct ventricular dilation, remodeling, and failure	106
ACE inhibitors in other cardiac conditions	108
Summary	108
References	109
CHAPTER 5 ACE Inhibitors for Congestive Heart Failure	117
Rationale for ACE inhibitors at each stage of development of myocardial failure	118
ACE inhibitors as preventative therapy for early myocardial failure	122
Possible use of ACE inhibitors as first-line therapy in heart failure	124
ACE inhibitors as second-line therapy with diuretics for congestive heart failure	125
ACE inhibitors as third component therapy in combination with diuretics and digoxin	128
ACE inhibition as part of quadruple therapy including diuretics, digoxin, and vasodilators	136
Diastolic dysfunction	137
Skeletal muscle metabolism in heart failure	137
Comparative studies of ACE inhibitors	138
ACE inhibitor therapy for congestive heart failure: success, tolerance, and failure	139
ACE inhibitors for congestive heart failure: contraindications and cautions	141
Cardiac contraindications to ACE inhibitor therapy	144
Recent large-scale trials: SOLVD, SAVE, AIRE, and others	145
Early phase infarct studies with ACE inhibitors	152
Summary	154
References	155

Contents	vii
CHAPTER 6 ACE Inhibitors and the Central Nervous System	162
Autonomic nervous system	162
Effects on cerebral perfusion	163
ACE inhibitors and stroke	164
Effects of ACE inhibitors on mood and other higher functions	166
Central antihypertensive mechanisms of ACE inhibitors	167
Summary	167
References	168
CHAPTER 7 ACE Inhibitors: Specific Agents: Pharmacokinetics	171
Classification	171
Alacepril	175
Altiopril (moveltipril)	176
Benazepril	176
Captopril	177
Ceranapril	182
Cilazapril	182
Delapril	186
Enalapril	188
Fosinopril	191
Lisinopril	194
Perindopril	197
Quinapril	201
Ramipril	204
Spirapril	206
Trandolapril	207
Zofenopril	208
Summary	208
References	209
CHAPTER 8 ACE Inhibitors: Side-Effects and Contraindications	218
Side-effects	218
Class side-effects	218
Side-effects initially described with high-dose captopril therapy	222
Contraindications to ACE inhibitors	224
Relative contraindications	224
Quality of life	225
Summary	226
References	227
CHAPTER 9 ACE Inhibitors: Drug Combinations and Interactions	229

viii	Contents	Contents	ix
Beta-blockers	229	Diabetic nephropathy	294
Diuretics	230	The ticking clock hypothesis	300
Calcium antagonists	232	Ageing	301
Alpha-blockers	233	Summary	302
Digoxin	233	References	302
Nonsteroidal anti-inflammatory agents	233		
Aspirin	234	APPENDIX 1: Summary of pharmacologic properties, clinical indications, and doses of ACE inhibitors	307
Lithium	235		
Probenecid	235	APPENDIX 2: ACE inhibitors: side-effects and contraindications	308
Interaction with diabetic therapy	235		
Summary	235		
References	236		
		Index	309
CHAPTER 10 ACE Inhibitors, Vascular Structure, and Arterial Disease in Hypertension	239		
Arterial physiology	240		
Endothelium in hypertension	246		
Arterioles in hypertension	247		
Arteriolar growth and wall/lumen ratio	248		
Large conduit (conducting) arteries in hypertension	253		
Hypothesis: large conduit arteries have a crucial role in perpetuating and increasing the severity of hypertension	254		
Effects of ACE inhibitors on arterial disease	258		
Reversal of vascular remodeling	262		
Summary	263		
References	263		
CHAPTER 11 ACE Inhibitors, Coronary Artery Disease, Ischemia, Arrhythmias, and Postinfarct Protection. Other Preventative Studies	268		
ACE inhibitors and atherosclerosis	268		
Protection against coronary events by ACE inhibitors	275		
Ventricular arrhythmias and ACE inhibitors	276		
Anti-ischemic effects of ACE inhibitors	277		
Trials in progress or recently reported	278		
Restenosis: a failed study	278		
Is cardioprotection now a valid concept in relation to the use of ACE inhibitors?	279		
Summary	282		
References	283		
CHAPTER 12 ACE Inhibitors and Metabolic Cardiovascular Syndrome. Diabetic Nephropathy. Ageing.	287		
Insulin and atheroma	287		
Diabetes mellitus and hypertension	293		